Mumbai, 23rd July 2024: Stemrx Biosciences Pvt Ltd introduced cutting-edge Microdose Infusion Therapy, a pioneering treatment for diabetic and metabolic diseases. This innovative approach involves administering insulin as a hormone instead of a drug, effectively addressing the root cause of diabetes and diabetes-related disorders and metabolic failure. By mimicking normal physiological processes, the MicroDose system significantly reduces insulin resistance, allowing for better absorption of blood sugar into cells and its conversion into energy.

Dr. Pradeep Mahajan, a renowned regenerative medicine expert at Stemrx Biosciences Pvt Ltd, is set to embark on a landmark visit to Houston, Texas. During this visit, Dr. Mahajan will participate in a leading-edge medical training session to bring this groundbreaking technology to Mumbai, India. The Micro Dose System (MDS) has demonstrated effectiveness in stopping the progression of diabetic and metabolic disasters.

“Micro Dose Infusion Therapy represents a significant advancement in the treatment of diabetes and Its related disorders,” says Dr. Pradeep Mahajan. “By addressing the root cause of metabolic failure, we are not just managing symptoms but potentially reversing the progression of the disease.”

Diabetes and diabetes-related complications are treated through Micro Dose Infusion Therapy. The underlying cause of the disease is addressed by this novel technique by simulating normal physiological processes, thus greatly lessening insulin resistance and improving absorption of blood sugar in addition to conversion into energy. Other disorders related to diabetes that can be effectively managed with Micro Dose Infusion Therapy include Cardiovascular Disease Neuropathy, Nephropathy, Retinopathy, and Peripheral Artery Disease.

The pancreatic β-cells play a crucial role in glucose homeostasis by secreting insulin, the only hormone capable of lowering blood glucose concentration. Impaired insulin secretion results in chronic hyperglycemia, a characteristic of type 2 diabetes (T2DM), currently affecting over 450 million people worldwide. The oscillatory release of insulin and glucose is essential to maintain metabolic balance. In diabetes patients, pancreatic β-cells often malfunction, leading to hepatic insulin resistance and the progression of type 2 diabetes.

“The goal of this technology is to mimic the body’s natural insulin response, thereby improving overall health and quality of life for patients,” Dr. Mahajan adds. “Our upcoming training in Houston is a crucial step in bringing this revolutionary treatment to patients in Mumbai.”

Common medications and lifestyle modifications often fail to fully address the long-term complications of diabetes, as they do not restore the natural periodic cycle of insulin in healthy physiology. The Micro Dose System, however, has shown promising results in improving bodily functions and halting the progression of chronic diseases related to diabetes. The oscillatory burst release of insulin in this therapy is achieved through a medical device that delivers insulin in a pattern mimicking the body’s natural response.

This landmark visit by Dr. Mahajan aims to bridge the gap between traditional diabetes treatments and advanced regenerative medicine. By introducing Micro Dose Infusion Therapy to India, Stemrx Biosciences Pvt Ltd hopes to offer patients a revolutionary alternative that targets the root cause of diabetes, providing hope for better health and improved quality of life.